Canaccord Genuity Maintains Buy on Globus Medical, Lowers Price Target to $105
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Caitlin Cronin maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $105.
Canaccord Genuity analyst Caitlin Cronin maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $105.